Get started
Author

Sławomir Mańdziuk

Observed names: Mandziuk, Sławomir, S Mańdziuk, S. Mandziuk, Slawomir Mandziuk, Slawomir Mańdziuk, Sławomir Mandziuk
ORCID: 0000-0002-9812-0777
Observed ORCID: 0000-0002-9812-0777
OpenAlex ID: A5050913534
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,484
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 762
Phytochemicals in Cancer Treatment and Cancer Prevention—Review on Epidemiological Data and Clinical Trials
2023 · Anna Rudzińska, Pola Juchaniuk, et al. · Nutrients · 245
PDF
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 224
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
2020 · D. Planchard, N. Reinmuth, et al. · Annals of Oncology · 157
PDF
New Directions in the Therapy of Glioblastoma
2022 · Katarzyna Szklener, Marek Mazurek, et al. · Cancers · 87
PDF
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2025 · Fabrice Barlesi, Wenxiu Yao, et al. · The Lancet · 82
Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity
2012 · Jaroslaw Dudka, Renata Gieroba, et al. · Evidence-based Complementary and Alternative Medicine · 80
PDF
New 1,3,4-Thiadiazole Derivatives with Anticancer Activity
2022 · Sara Janowska, Dmytro Khylyuk, et al. · Molecules · 78
PDF
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
2022 · Katarzyna Szklener, Adam Michalski, et al. · Cells · 49
PDF
Characteristics of Fluorescent Intraoperative Dyes Helpful in Gross Total Resection of High-Grade Gliomas—A Systematic Review
2020 · Marek Mazurek, Bartłomiej Kulesza, et al. · Diagnostics · 32
PDF
Evolution of Theories on Doxorubicin-Induced Late Cardiotoxicity-Role of Topoisomerase
2024 · Jaroslaw Szponar, Erwin Ciechanski, et al. · International Journal of Molecular Sciences · 29
PDF
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
2021 · Aleksandra Bożyk, Paweł Krawczyk, et al. · Archives of Medical Science · 29
PDF
Enhancing glioblastoma treatment through the integration of tumor-treating fields
2023 · Katarzyna Szklener, Mateusz Bilski, et al. · Frontiers in Oncology · 28
PDF
Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats
2018 · Andrzej Wróbel, Anna Serefko, et al. · European Journal of Pharmacology · 26
Thiazolidin-4-one-based derivatives – Efficient tools for designing antiprotozoal agents. A review of the last decade
2023 · Helena Tuszewska, Jacek Szczepański, et al. · Bioorganic Chemistry · 24
New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors
2022 · Katarzyna Szklener, Paulina Chmiel, et al. · Cancers · 22
PDF
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
2021 · Anna Grenda, Paweł Krawczyk, et al. · Frontiers in Oncology · 21
PDF
Exceptional Survival with Lorlatinib in ALK-Rearranged Lung Cancer: A Case Report
2023 · Katarzyna Szklener, Karolina Nieoczym, et al. · Asian journal of Current Research in Clinical Cancer · 20
PDF
Dietary Supplements in Chemotherapy-Induced Peripheral Neuropathy: A New Hope?
2022 · Katarzyna Szklener, Sebastian Szklener, et al. · Nutrients · 20
PDF
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
2018 · D.M. Kowalski, N. Reinmuth, et al. · Annals of Oncology · 18
PDF
The differential effects of green tea on dose-dependent doxorubicin toxicity
2015 · Slawomir Mandziuk, Renata Gieroba, et al. · Food & Nutrition Research · 18
PDF
The Redox Imbalance and the Reduction of Contractile Protein Content in Rat Hearts Administered with L-Thyroxine and Doxorubicin
2012 · Agnieszka Korga, Jaroslaw Dudka, et al. · Oxidative Medicine and Cellular Longevity · 18
PDF
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
2025 · Dejan Juric, Daniel Anderson, et al. · Cancer Research Communications · 17
PDF
Ozone in Chemotherapy-Induced Peripheral Neuropathy—Current State of Art, Possibilities, and Perspectives
2023 · Katarzyna Szklener, Anna Rudzińska, et al. · International Journal of Molecular Sciences · 17
PDF
Works count: 117
Citation count: 4,823
H-index: 20
I10-index: 35
Year
Topic
Type